Immunogenicity of a trivalent recombinant antigen based on SARS-CoV-2 receptor- binding domain and its variants of concern

Authors

• Berenice Calderón-Pérez, CINVESTAV-IPN, MexicoFollow
• Leandro Alberto Núñez-Muñoz, Departamento de Biotecnología y Bioingeniería CINVESTAV-IPN
• Lady Laura Trejo-Ayala, Departamento de Biotecnología y Bioingeniería CINVESTAV-IPN
• Víctor Hugo Rosales-García, Unidad de Citometría CINVESTAV-IPN
• Benjamín Emmanuel Chávez-Álvarez, UPEAL CINVESTAV-IPN
• Roberto Ruiz-Medrano, Departamento de Biotecnología y Bioingeniería CINVESTAV-IPN
• Beatriz Xoconostle-Cázares, Departamento de Biotecnología y Bioingeniería CINVESTAV-IPN

Conference Dates

May 19 - 24, 2024

Abstract

Please click Additional Files below to see the full abstract.

Recommended Citation

Berenice Calderón-Pérez, Leandro Alberto Núñez-Muñoz, Lady Laura Trejo-Ayala, Víctor Hugo Rosales-García, Benjamín Emmanuel Chávez-Álvarez, Roberto Ruiz-Medrano, and Beatriz Xoconostle-Cázares, "Immunogenicity of a trivalent recombinant antigen based on SARS-CoV-2 receptor- binding domain and its variants of concern" in "Vaccine Technology IX", Linda Lua, The University of Queensland, Australia; Charles Lutsch, Sanofi-Vaccines, France; Francesc Gòdia, Universitat Autònoma de Barcelona (UAB), Spain; Tara Tagmyer, CMC Leader, USA Eds, ECI Symposium Series, (2024). https://dc.engconfintl.org/vaccine_ix/41